Gastroenterology Insights — Clinical Updates, Guides & Resources — Page 6

14 min readJun 1, 202624reads

The Future of Gastroenterology Intelligence: How HIPAA-Ready, GI-Specialized AI Is Reshaping Care

Gastroenterology has become an information-dense specialty. Clinicians are expected to synthesize expanding biomedical literature, rapidly changing GI guidelines, EHR data, pathology, imaging, endoscopy findings, and late-breaking conference updates while still making safe, time-sensitive decisions at the bedside and in the endoscopy suite. That challenge is not unique to GI, but it is especially visible in a field that spans hepatology, inflammatory bowel disease, GI oncology, screening and surveillance, pancreaticobiliary disease, motility, nutrition, and complex procedural care. Reviews of healthcare information overload and EHR-related cognitive burden have linked this environment to workflow strain and patient-safety risk, while PubMed alone now indexes more than 40 million biomedical citations. [1] The strategic opportunity is not “more AI” in the abstract. It is better clinical intelligence: HIPAA-ready AI that is specialized for gastroenterology, grounded in current society guidance, designed for human oversight, and capable of adapting its output to the user’s role. Recent reviews across NIH/PubMed, WJGNet, Gastroenterology, AMEgroups, and ScienceDirect describe real momentum for gastroenterology AI in endoscopy, IBD, hepatology, oncology, decision support, and education, but they also emphasize unresolved issues around hallucination, liability, bias, interoperability, and real-world validation. [2] The editorial implication is straightforward: generic search and general-purpose language models are not enough for high-stakes GI care. A safer path is GI-specialized, mode-adaptive, governed deployment. In practical terms, that means systems that can support gastroenterology education for fellows, GI clinical decision support for specialists, and responsible patient-facing communication—while respecting HIPAA, working within EHR interoperability standards, and remaining subordinate to clinician judgment. [3] The information challenge in modern gastroenterology If one wanted to design a specialty that exposes the limits of fragmented information workflows, gastroenterology would be a good candidate. A single week in GI practice may require the clinician to move from MASLD fibrosis risk stratification to inpatient severe ulcerative colitis rescue therapy, from Barrett’s esophagus surveillance to acute pancreatitis, and from HCC screening questions to post-polypectomy surveillance logic. Professional society libraries reflect that complexity: AGA maintains large, continuously updated clinical guidance collections, and ACG’s guidance library spans Crohn’s disease, ulcerative colitis, acute pancreatitis, focal liver lesions, preventive IBD care, colorectal cancer screening, Barrett’s esophagus, and more. [4] Major GI domains are each evolving on their own timetable In hepatology, the knowledge burden alone is substantial. AGA’s 2026 MASLD clinical care pathway explicitly integrates newer nomenclature, noninvasive fibrosis risk stratification, and emerging therapies; AASLD’s current hepatology guidance infrastructure separately emphasizes chronic hepatitis B prevention, surveillance, and treatment; and cirrhosis management remains tightly linked to recurring surveillance and complication-prevention tasks, including HCC screening every six months. This is not a narrow knowledge lane but a layered one: MASLD, cirrhosis, hepatitis, portal hypertension, transplant referral, and HCC all sit in the same operational ecosystem. [5] IBD is similarly multidimensional. The current ACG guideline library includes updated 2025 guidelines for both Crohn’s disease and ulcerative colitis, while AGA’s inpatient IBD guidance emphasizes hospitalization thresholds, complication assessment, biomarkers, endoscopic evaluation when indicated, prophylactic anticoagulation, timely colectomy counseling in severe ulcerative colitis, and rapid response monitoring. In parallel, gastroenterology AI reviews describe growing use cases for AI in capsule endoscopy, relapse prediction, and disease personalization. The result is a care pathway that is not only evidence-heavy, but sequence-heavy: timing, triage, rescue, discharge planning, and longitudinal monitoring all matter. [6] GI oncology adds another layer of risk-based nuance. AGA’s Barrett’s esophagus guideline now emphasizes personalized surveillance and high-quality endoscopy, while its gastric cancer guidance stresses that endoscopy is the best test for screening and surveillance in high-risk individuals and identifies H. pylori eradication as essential to prevention strategy. Hepatology adds a parallel cancer-surveillance logic: AGA advises HCC screening for patients with NAFLD-related cirrhosis or advanced fibrosis, and notes that alternative imaging should be considered every six months when ultrasound quality is suboptimal. These are precisely the kinds of decisions that defeat simplistic lookup tools because the correct answer depends on the interplay among risk, interval, modality, and patient phenotype. [7] Endoscopy and pancreaticobiliary disease reinforce the same point. AGA’s 2025 CADe guidance concluded that AI-assisted technology helps identify colorectal polyps but that its effect on colorectal cancer prevention remains unclear, leading the panel to make no recommendation for or against routine CADe-assisted colonoscopy because evidence on long-term outcomes remains very low certainty. At the same time, ESGE’s 2025 position statement treats AI-assisted CADe in screening and surveillance colonoscopy as a serious clinical guidance question, and upper-GI AI reviews in Gastroenterology describe encouraging results in lesion detection. Meanwhile, pancreatic care ranges from the first 48–72 hours of acute pancreatitis management to years-long surveillance decisions for neoplastic pancreatic cysts, where strategies can differ markedly in intensity and stopping rules. [8] Journals, guidelines, and conferences are now a single knowledge stream Modern GI practice is no longer updated by journals alone. DDW describes itself as the premier meeting for professionals in gastroenterology, hepatology, GI endoscopy, and related fields, while UEG Week positions itself as a major annual multidisciplinary congress for digestive health. DDW also notes that conference abstracts are published in supplements to Gastroenterology and Gastrointestinal Endoscopy , illustrating how conference intelligence feeds the formal literature. In other words, the clinician who wants current hepatology updates or endoscopy advances must increasingly track journals, society guidelines, and conference outputs together. [9] This is where the phrase gastroenterology intelligence becomes more useful than the phrase “AI tool.” The actual need is a system that can organize, contextualize, and safely retrieve specialty knowledge at the point of use. Search alone is not enough when the user is trying to decide not just what exists , but what applies now, to this patient, in this workflow, under this guideline frame. [10] Why generic search is not enough for GI clinical decision support Generic web search is built to return results, not to perform clinical reasoning. General-purpose large language models are better than traditional search at synthesis, but gastroenterology literature increasingly warns against treating them as specialty-safe by default. A 2024 systematic review of LLMs in gastroenterology described benefits in diagnostic support, documentation, specialist education, and patient engagement; yet other GI reviews explicitly warned that general-purpose LLMs can have unacceptably low accuracy on clinical gastroenterology and hepatology tasks, with potential patient-safety implications. A 2025 review focused on clinical decision support in gastroenterology and hepatology similarly identified persistent problems with bias, hallucinations, interoperability barriers, and training needs. [11] That distinction matters clinically. A generic model may summarize a topic well enough for background reading, but GI clinical decision support demands more than summary. It requires specialty context, temporality, and the ability to hold ambiguity without fabricating certainty. The decision about severe UC rescue therapy, HCC surveillance in obesity-limited ultrasound, Barrett’s interval nuance, or MASLD fibrosis stratification is not merely a recall task. It is a reasoning task constrained by evidence quality, society recommendations, and local workflow. [12] The AGA CADe example is instructive. In many product narratives, a rise in adenoma detection rate would be enough to frame AI as an automatic quality upgrade. But AGA’s 2025 guidance did not treat a surrogate improvement as equivalent to proof of long-term benefit; it highlighted the very low certainty of evidence for CRC incidence, CRC mortality, and post-colonoscopy colorectal cancer outcomes. That is exactly the kind of nuance that a GI-specialized intelligence layer should surface rather than flatten. [13] This is also why medical AI for gastroenterology should be evaluated against workflow tasks rather than generic benchmark mythology. Can it retrieve the right guidance set? Can it separate patient education from clinician reasoning? Can it recognize when evidence is unsettled? Can it identify when a response requires escalation rather than completion? Modern GI practice will reward systems that know their limits at least as much as systems that answer quickly. [14] What HIPAA-ready, GI-specialized AI should mean “HIPAA-ready AI” should not be treated as a decorative label. HHS states that the HIPAA Privacy Rule establishes national standards for protecting medical records and other individually identifiable health information, and its cloud-computing guidance makes clear that cloud service providers and their customers have defined responsibilities when ePHI is created, received, maintained, or transmitted through cloud services. HHS also maintains formal guidance for de-identification through two recognized pathways—Safe Harbor and Expert Determination—which is particularly relevant for model development, testing, and secondary-use analytics. [15] In practice, then, a HIPAA-ready AI deployment in gastroenterology should imply clearly mapped data flows, role-based access, auditability, appropriate contracting and business-associate arrangements where required, secure cloud architecture, minimum-necessary thinking, and a deliberate decision about whether data remain identifiable, are limited, or are de-identified. For patient-facing digital surfaces, covered entities also need to think about HHS OCR’s guidance on online tracking technologies. The important point is that HIPAA-ready AI is not an abstract model property; it is an operational property of a governed deployment. [16] Regulatory scope also matters. FDA’s 2026 guidance on clinical decision support software clarifies that some CDS functions may fall outside device regulation under the 21st Century Cures Act, while other software functions remain subject to FDA’s digital-health framework depending on intended use. For health-system buyers, that means governance cannot stop at prompt quality or vendor demos; it must also include intended-use claims, escalation pathways, and documentation of what the system is and is not authorized to do. [17] Specialization matters because gastroenterology is not a generic use case A growing literature across Gastroenterology , WJGNet, AMEgroups, and ScienceDirect converges on a consistent point: AI in GI is broadest and most promising where it is domain-aware—endoscopy, hepatobiliary disease, pancreas, IBD, imaging, pathology, and clinical decision support—rather than generic and untethered. ScienceDirect’s 2025 hepatology scoping review mapped AI applications across imaging, histopathology, chronic liver disease, cirrhosis, and transplantation; WJGNet’s cross-GI reviews similarly span the upper and lower GI tract, IBD, hepatobiliary disease, and pancreas; and Gastroenterology ’s implementation review stresses that deployment barriers are as important as technical performance. [18] One useful design implication is mode adaptation . Gastroenterology education, GI clinical decision support, and patient communication are not the same task. A fellow preparing for rounds may need mechanistic explanation and prioritization. An attending may need structured reasoning against current GI guidelines. A patient may need plain-language explanation, reassurance, safety-netting, and avoidance of unnecessary alarm. Reviews of LLMs in gastroenterology explicitly discuss specialist education, patient engagement, and patient communication as distinct application categories, which supports the idea that a single undifferentiated response style is a poor fit for specialty care. [19] GastroAGI as an example of role-adaptive design A platform such as GastroAGI is most interesting, editorially, not because it is “AI for GI,” but because it treats the specialty as a set of layered users and tasks. In that framing, Student Mode supports gastroenterology education, Clinician Mode supports structured GI clinical decision support, and Patient Mode supports simplified, responsible communication. That is a stronger design thesis than simply attaching a chatbot to a guideline library. According to the internal GastroAGI stress-test summary provided for this draft, the platform was evaluated with role-specific prompts across Student, Clinician, and Patient modes. The reported objective was not to prove superiority against external benchmarks but to assess mode separation, response appropriateness, reasoning behavior, safety framing, and hallucination frequency. Internal summary scores were 8.4/10 for Student Mode, 8.7/10 for Clinician Mode, and 9.0/10 for Patient Mode, with the organization reporting clear behavioral separation among modes and relatively low hallucination in the tested set. Those findings are directionally encouraging, but they should be presented as preliminary internal data pending independent external validation and prospective workflow study. External GI and clinical-AI literature strongly supports this kind of staged safety and trust evaluation. [20] What further distinguishes a GI-specialized platform is not merely conversational capability but the breadth and organization of specialty knowledge available to the user. Gastroenterology evolves through multiple parallel information streams—guidelines, peer-reviewed journals, conference presentations, procedural innovations, disease-specific pathways, and emerging therapeutic evidence. A practical intelligence layer therefore benefits from reflecting the structure of the specialty itself. In that context, GastroAGI organizes information across a broad spectrum of digestive-health domains rather than concentrating on a single disease category or procedural niche. The platform includes continuously updated topic environments spanning hepatology, inflammatory bowel disease, gastrointestinal oncology, endoscopy, liver transplantation, cirrhosis, hepatocellular carcinoma, upper gastrointestinal disease, pancreaticobiliary disorders, GI surgery, and basic sciences relevant to digestive disease. Hepatology remains one of the clearest examples of why this matters. Contemporary liver practice now requires clinicians and trainees to navigate MASLD nomenclature, fibrosis risk stratification pathways, viral hepatitis management, portal hypertension, cirrhosis complications, transplant evaluation, and HCC surveillance recommendations that continue to evolve alongside emerging therapies and guideline updates. A platform designed around gastroenterology intelligence can help organize these knowledge layers into more clinically usable pathways rather than leaving users to navigate fragmented searches across multiple sources. Similarly, inflammatory bowel disease care increasingly combines guideline-directed therapy with longitudinal monitoring, biologic sequencing, inpatient management decisions, therapeutic drug monitoring, and patient-centered counseling. The information burden extends beyond treatment algorithms alone and increasingly includes biomarker interpretation, disease monitoring, procedural timing, and emerging evidence presented through major meetings and specialty literature. Role-adaptive systems may therefore support not only information retrieval but also educational prioritization and communication clarity. Procedural gastroenterology introduces another dimension. Endoscopy is increasingly shaped by advances in lesion characterization, quality metrics, artificial-intelligence-assisted detection systems, therapeutic interventions, and surveillance frameworks. Questions surrounding colorectal screening, Barrett’s esophagus, pancreaticobiliary endoscopy, and upper-GI lesion detection often require interpretation that depends on context rather than isolated facts. A GI-specialized information platform may therefore be more useful when it presents evidence alongside procedural reasoning and workflow relevance. The same logic applies to GI oncology and pancreaticobiliary disease. Clinicians frequently move among HCC surveillance strategies, gastric and colorectal cancer prevention, pancreatic cyst follow-up, biliary disorders, and multidisciplinary management pathways. These areas are updated not only through formal guideline publications but also through rapidly evolving conference intelligence and subspecialty literature. Educational and decision-support environments that maintain awareness of such developments may therefore provide greater continuity than static reference repositories. Importantly, GastroAGI also reflects the educational diversity of the specialty. Alongside advanced clinical topics, the platform includes dedicated environments for basic sciences, exam-oriented learning, and foundational digestive-pathophysiology concepts. This structure recognizes that gastroenterology learning occurs across multiple levels—from medical students and trainees building conceptual frameworks to practicing clinicians seeking focused evidence summaries and workflow support. Viewed through this lens, the platform is less a generic chatbot and more an evolving gastroenterology knowledge environment organized around specialty domains, user roles, and practical workflows. Whether this model ultimately improves clinical efficiency, education, or decision quality will require continued validation. Yet the broader design principle remains compelling: modern GI practice increasingly benefits from intelligence systems that are specialty-aware, role-adaptive, and continuously aligned with the expanding information ecosystem of digestive disease. Practical workflows and implementation in health systems The most credible near-term use cases for gastroenterology AI are bounded, evidence-aware, and workflow-specific. In hepatology, a system can help organize MASLD fibrosis pathways, summarize chronic hepatitis B updates, or turn HCC surveillance rules into actionable reminders for the right risk groups. In IBD, it can prepare problem-oriented syntheses for hospitalization, discharge planning, biologic decision discussions, or patient education. In endoscopy, it can support surveillance interval logic, preprocedure counseling, or digest late-breaking meeting summaries into subspecialty briefs. In patient communications, it can translate specialist reasoning into plain language without changing the clinical plan. [21] EHR integration should follow modern interoperability standards instead of bespoke copy-paste workflows whenever possible. ONC describes HL7 FHIR as a widely used API-focused standard for representing and exchanging health information, and the ONC standards hub includes both CDS Hooks and SMART on FHIR application-launch frameworks in the contemporary interoperability stack. This matters because GI intelligence systems should fit inside the chart, inbox, and documentation environment clinicians already use—rather than forcing them into yet another disconnected window. [22] At the same time, responsible implementation requires humility. Gastroenterology ’s implementation review emphasizes regulatory, ethical, and governance barriers; AMEgroups highlights liability ambiguity and the need for legal clarity; and NIST’s AI Risk Management Framework is explicitly positioned as a tool for organizations—including healthcare users—to manage AI risk. In practice, that argues for phased rollouts, local validation, red-teaming, post-deployment monitoring, audit logs, feedback capture, and clear human-override expectations. [23] A real-world endoscopy example helps here. Penn Gastroenterology and Hepatology publicly described its adoption of GI Genius for real-time colon polyp detection during colonoscopy, presenting a concrete example of how AI enters GI care first as an assistive layer within a defined clinical domain. That is a useful model for broader GI intelligence deployment: start where the task is bounded, the workflow is visible, and the clinician remains decisional. [24] Future directions and research needs The next phase of gastroenterology AI should shift from novelty to evidence. The specialty needs more prospective studies that test not only answer quality but also workflow impact, decision quality, patient comprehension, documentation burden, equity, and downstream outcomes. It also needs external validation across community and academic settings, multilingual patient populations, varying endoscopy quality environments, and different EHR architectures. A system that performs well in one referral center or one internal benchmark may not generalize safely elsewhere. [25] Research priorities are also becoming clearer. GI needs source-grounded hallucination measurement, trustworthy citation behavior, specialty-specific safety taxonomies, governance models for patient-facing use, and stronger evidence on cost-effectiveness and clinician trust. It is increasingly plausible that the winning systems in this space will not be the most verbally fluent, but the most auditable, interoperable, role-aware, and operationally dependable. That is the real future of gastroenterology intelligence: not replacing specialists, but helping them navigate a specialty whose information burden now exceeds the capacity of unguided search. [26]

GastroAGI TeamRead more

6 min readJun 1, 202624reads

HER2-Positive Gastroesophageal Cancer in 2026: How HERIZON-GEA-01 Resets the First-Line Standard

A 58-year-old male presents with progressive dysphagia, a 9 kg weight loss over three months, and a biopsy-confirmed HER2-positive gastroesophageal junction adenocarcinoma. Staging shows liver metastases. His PD-L1 combined positive score comes back at 2. Until last week, this was a trastuzumab-plus-chemotherapy case with a few nuanced arguments for adding pembrolizumab. The HERIZON-GEA-01 trial, published in the New England Journal of Medicine on May 28, 2026, changed the conversation for exactly this patient. HER2-positive disease accounts for approximately 20% of gastroesophageal adenocarcinoma (GEA) cases, and it has carried a disproportionately poor prognosis despite the availability of targeted therapy. Trastuzumab became the first-line backbone after the ToGA trial in 2010 - a result built on a modest overall survival benefit of roughly 2.7 months. For 16 years, that modest gain was the ceiling. The clinical question driving HERIZON-GEA-01 was straightforward: can a dual HER2-targeting bispecific antibody built to hit two non-overlapping epitopes simultaneously outperform a single-domain binder that has been the standard since gastroesophageal oncology was a subspecialty niche? And does adding a PD-1 checkpoint inhibitor extend that benefit further - including in patients whose tumours don't express PD-L1? Much like resmetirom becoming the first approved drug for NASH with fibrosis rewrote the MASLD treatment algorithm, the answer to both questions here reshapes the first-line standard for HER2-positive GEA. Based on zanidatamab HER2-positive gastroesophageal cancer first-line treatment data from 914 patients across three continents, the answer to both is yes. What Zanidatamab Is and Why It Was Expected to Outperform Trastuzumab Zanidatamab is a bispecific IgG1-like antibody that binds two distinct, non-overlapping HER2 epitopes - domain 2 (the trastuzumab binding site) and domain 4 (the pertuzumab binding site) - on the same molecule. That simultaneous dual epitope occupancy drives receptor crosslinking and internalisation, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity through mechanisms that a monospecific antibody cannot replicate at the same receptor density. In HER2-overexpressing tumours, where receptor copy number is already high, this translates to a more efficient and sustained suppression of HER2 signalling than trastuzumab alone. The phase Ib/II data that preceded HERIZON-GEA-01 were compelling enough to justify a phase 3. In patients with previously untreated, unresectable HER2-positive gastric and gastroesophageal junction cancer treated with zanidatamab plus tislelizumab plus CAPOX chemotherapy, the confirmed objective response rate was 75.8%, median duration of response was 23.3 months, and median overall survival reached 32.4 months - figures that had not been seen in this disease setting. HERIZON-GEA-01 enrolled 914 patients with centrally confirmed HER2-positive advanced GEA and no prior systemic therapy, randomising them 1:1:1 to three arms: zanidatamab plus chemotherapy (n=304), zanidatamab plus tislelizumab plus chemotherapy (n=302), or trastuzumab plus chemotherapy as the control (n=308). Chemotherapy was physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil plus cisplatin. The two primary endpoints were progression-free survival and overall survival. Central HER2 confirmation was mandatory - a methodological rigour that matters when interpreting the magnitude of the treatment effect. Clinical Scenario Case in Point A 61-year-old man with ECOG performance status 1 presents with a 4-month history of dysphagia and a 10 kg weight loss. Upper endoscopy and biopsy confirm gastroesophageal junction adenocarcinoma; central HER2 testing returns IHC 3+. CT staging identifies two hepatic lesions and para-aortic lymphadenopathy. PD-L1 combined positive score on the biopsy specimen is less than 1. He has no prior systemic therapy and no significant cardiopulmonary comorbidities. Pre-HERIZON-GEA-01 practice left this patient in an uncomfortable grey zone: trastuzumab plus chemotherapy was standard, KEYNOTE-811 offered the option of adding pembrolizumab, but the PD-L1 negativity created a legitimate clinical question about the magnitude of checkpoint inhibitor benefit in this specific patient. Post-HERIZON-GEA-01, the decision is more straightforward. The trial demonstrated that the OS benefit of zanidatamab plus tislelizumab plus chemotherapy was consistent across PD-L1 subgroups - an effect that does not map onto pembrolizumab's PD-L1-dependent behaviour in this disease. This patient, previously in a treatment grey zone because of his PD-L1 score, now has a clearly supported regimen with the longest median OS reported in first-line HER2-positive GEA. The conversation with him shifted from "the data on checkpoint inhibitors in PD-L1-negative disease are limited" to "the triple combination showed benefit irrespective of PD-L1 status in a 914-patient phase 3 trial." Reading the Efficacy and Safety Numbers - What Actually Matters Clinically The headline numbers from HERIZON-GEA-01 are clear, but the detail that clinicians should carry into practice is the duration of response gap, not just the survival curves. Confirmed objective response rates across the three arms were similar - 69.6% with zanidatamab plus chemotherapy, 70.7% with the triple combination, and 65.7% with trastuzumab plus chemotherapy. Responses are not the differentiator. What separates these regimens is how long those responses last. Median duration of response was 14.3 months in the zanidatamab plus chemotherapy doublet, 20.7 months in the triple combination arm, and 8.3 months in the trastuzumab control arm. The gap between 20.7 and 8.3 months represents more than a statistical improvement - it reflects a fundamentally different disease trajectory for a patient sitting across the clinic table asking how long a response might hold. Overall survival with zanidatamab plus tislelizumab plus chemotherapy reached a median of 26.4 months compared to 19.2 months with trastuzumab plus chemotherapy (hazard ratio for death 0.72; 95% CI 0.57–0.90; P=0.004). For the first time in this disease, more than half of patients in a phase 3 trial were alive at two years. That 2-year OS rate is the benchmark this disease setting has not previously cleared. On safety, diarrhea was the dominant treatment-related adverse event - reported in 100% of patients in the phase Ib/II zanidatamab-tislelizumab combination data and confirmed as the leading toxicity in the phase 3 context. This is not an unexpected signal for a dual-HER2 targeting antibody, and it is manageable with early anti-diarrheal prophylaxis. The overall safety profile was characterised as manageable by the trial investigators, with no new safety signals beyond the established class effects of the component agents. For patients with prior gastrointestinal motility concerns or inflammatory bowel disease, a proactive bowel management protocol from cycle 1 is warranted. The zanidatamab-plus-chemotherapy doublet, without tislelizumab, also outperformed trastuzumab on duration of response (14.3 vs 8.3 months), establishing it as a viable option where checkpoint inhibitors are genuinely contraindicated - autoimmune disease on active immunosuppression, prior severe immune-related adverse events, or organ transplant recipients. A Frequently Overlooked Point - PD-L1 Score Should Not Exclude Patients from the Triple Regimen The finding that tislelizumab's contribution to overall survival held across PD-L1-negative tumours will be the most commonly misapplied aspect of these data in routine practice. The reflex to reserve checkpoint inhibitors for high-CPS patients is reasonable when the drug in question is pembrolizumab layered onto trastuzumab - that is the biology KEYNOTE-811 studied. It does not transfer cleanly here. Zanidatamab's dual HER2 epitope targeting appears to reshape the tumour microenvironment in ways that make PD-1 blockade effective independent of baseline PD-L1 expression, likely through enhanced ADCC-mediated immune cell recruitment. Until the PD-L1 subgroup analyses presented at ASCO 2026 are fully published, the default position should be to offer the triple combination to all eligible patients with advanced HER2-positive GEA - not to apply a PD-L1 threshold borrowed from a different drug, in a different mechanism context, against a less potent HER2-targeted backbone. When you are managing a HER2-positive GEA case and need to think through regimen selection, PD-L1 status, performance status constraints, or toxicity management - walk GastroAGI through the clinical details. It will return a reasoned, guideline-anchored response in seconds, grounded in the data that just changed this disease. For how the same approach applies to another GI cancer where NEJM trial data is reshaping management, see daraxonrasib in RAS-mutated pancreatic cancer .

GastroAGI TeamRead more

7 min readMay 25, 202633reads

FIB-4 in MASLD: When to Trust It, When It Fails, and What to Do in the Grey Zone

Your patient is a 54-year-old woman with type 2 diabetes, a BMI of 33, and incidentally detected hepatic steatosis on abdominal ultrasound. You calculate her FIB-4 - it comes back at 1.1, which puts her in the low-risk category. You file it, reassure her, and plan a repeat in a year. Two years later she re-presents with fatigue and a platelet count of 118. Her FibroScan shows liver stiffness of 11.2 kPa. She has bridging fibrosis. The FIB-4 missed it. This post explains exactly why, and what your workup should have looked like. FIB-4 MASLD liver fibrosis staging has become the default first step in most outpatient referral pathways - and for good reason. It uses four variables you already have (age, AST, ALT, platelet count), requires no imaging, costs nothing, and carries guideline endorsement from both the AGA and EASL. The March 2026 AGA Clinical Care Pathway for MASLD explicitly recommends FIB-4 as the first-line tool to stratify fibrosis risk in at-risk patients before any further investigation. That guidance is sound in broad populations. The problem is that the patients who land in your clinic are rarely a broad population. They are diabetic, obese, older, or all three - and that is precisely where FIB-4's diagnostic performance degrades in ways the standard thresholds do not warn you about. A January 2026 paper in JHEP Reports, drawing from primary care MASLD cohorts in Belgium and the Netherlands, demonstrated that FIB-4 systematically under-triages patients with type 2 diabetes or BMI ≥30, even when the score falls below the 1.30 threshold typically used to exclude significant fibrosis. In other words, a score that should be reassuring is not, in the metabolic patients who make up the majority of your MASLD caseload. Understanding where FIB-4 breaks down - and how to navigate that grey zone - is now a core clinical competency, not an optional nuance. What FIB-4 Actually Measures - and Where the Thresholds Come From FIB-4 was originally validated in HIV/HCV co-infected patients in 2006, then adopted broadly across chronic liver disease. Its formula - (age × AST) / (platelet count × √ALT) - is a surrogate for portal hypertension-associated platelet destruction and hepatocyte injury. It performs reliably at the extremes: a score below 1.30 has a high negative predictive value for advanced fibrosis in general MASLD populations, and a score above 2.67 carries high specificity for significant fibrosis. The indeterminate zone between 1.30 and 2.67 is where most clinical decisions stall. What the validation studies cannot fix is a structural issue: FIB-4 is not fibrosis-specific. It reflects the metabolic and inflammatory milieu as much as the fibrotic burden. In patients with type 2 diabetes, chronically elevated AST from insulin resistance inflates the numerator independently of fibrosis stage. In obese patients, thrombocytosis from the pro-inflammatory state artificially suppresses the score by boosting the denominator. Both effects push the result toward the low-risk range even when the liver is accumulating collagen at F2 or F3 stage. A meta-analysis published in the International Journal of Hepatology in 2026, analysing 14 studies across 5,521 MASLD patients, found that FIB-4 at the standard 1.30 cut-off missed a clinically significant proportion of advanced fibrosis cases - with accuracy declining further in cohorts with higher rates of diabetes and obesity. This is not a fringe finding. It is a systematic limitation that applies directly to the patients most likely to progress. Clinical Scenario A 61-year-old man with a 12-year history of type 2 diabetes and a BMI of 34 is referred from his GP after an ultrasound reports moderate hepatic steatosis. His liver enzymes are mildly elevated - ALT 52 U/L, AST 41 U/L. Platelet count is 196 × 10⁹/L. FIB-4 calculates to 1.18. Standard pathway would classify him as low risk and discharge back to primary care with annual monitoring. Instead, recognising his dual metabolic risk flags - diabetes and obesity, both documented FIB-4 confounders - you refer him for vibration-controlled transient elastography (VCTE). His liver stiffness measurement comes back at 9.4 kPa, consistent with F3 fibrosis. CAP score confirms significant steatosis. He is referred for hepatology input, commenced on lifestyle intervention, and enrolled in a GLP-1 trial. Without the elastography step, this patient's bridging fibrosis would have been missed for at least another year - the window where antifibrotic intervention has the most impact. What to Do When FIB-4 Falls in the Low or Indeterminate Range but Risk Factors Are High The 2026 JHEP Reports data provide a practical rule that is not yet embedded in most referral guidelines: in patients with MASLD plus diabetes or BMI ≥30, do not use a FIB-4 below 1.30 as a standalone rule-out for significant fibrosis. These patients warrant second-line non-invasive fibrosis assessment regardless of the FIB-4 result. The preferred second-line tool in most settings is VCTE (FibroScan). A liver stiffness measurement below 8 kPa in a fasted, adequately windowed patient provides reliable exclusion of F3–F4 fibrosis. Above 8 kPa - or where VCTE is unavailable or technically limited by BMI - MR elastography offers superior accuracy and is increasingly accessible at tertiary centres. For clinical settings where elastography access is limited, the Enhanced Liver Fibrosis (ELF) panel is an evidence-based serum alternative; an ELF score ≥9.8 should trigger liver specialist referral regardless of FIB-4 result. Liver biopsy remains the reference standard when non-invasive tests conflict, when the clinical picture suggests a competing aetiology contributing to fibrosis acceleration (alcohol, metabolic syndrome combined with viral hepatitis, drug-induced injury), or when treatment-trial eligibility requires histological staging. When to biopsy MASLD is not a binary question driven by FIB-4 alone - it is a sequential decision that accounts for the full metabolic profile. For an updated take on what happens once staging confirms MASH with fibrosis, see GastroAGI's deep-dive on sequencing resmetirom and GLP-1 therapy in confirmed MASH with fibrosis . A Frequently Overlooked Point: Age Inflates FIB-4 Without Reflecting True Fibrosis Burden Clinicians rarely scrutinise the age term in the FIB-4 formula, but they should. Because age multiplies directly against AST in the numerator, an older patient with even mildly elevated transaminases will generate a higher FIB-4 score regardless of fibrotic activity. The converse is equally important: in younger patients - those under 35 with early MASLD - FIB-4 frequently underestimates fibrosis because a low age term deflates the score even when hepatic inflammation is active. Both groups warrant elastography-based confirmation rather than reliance on FIB-4 at face value. The score was not designed to be age-agnostic, and managing it as if it were produces predictable misclassifications at both ends of the age spectrum. Bottom Line for Clinical Practice Do not use FIB-4 <1.30 as a standalone rule-out in MASLD patients with type 2 diabetes or BMI ≥30 - the false-negative rate in this subgroup is clinically unacceptable. Proceed to VCTE. VCTE threshold of 8 kPa is the practical trigger for specialist referral in patients with indeterminate or falsely reassuring FIB-4; above this threshold, F3+ fibrosis is likely. The indeterminate zone (FIB-4 1.30–2.67) should always prompt second-line testing - it is not a safe holding category, particularly in older or diabetic patients. ELF ≥9.8 warrants hepatology referral even if FIB-4 is low , particularly where VCTE is unavailable or technically limited. If that referral reveals decompensated disease, the GastroAGI guide on managing decompensated cirrhosis once fibrosis progresses covers the next decision layer. Liver biopsy is not the answer to every diagnostic question in MASLD , but it remains essential when non-invasive tests conflict, competing aetiologies are present, or treatment-trial enrolment requires histological staging. If advanced disease is confirmed and the patient deteriorates acutely, the framework for distinguishing ACLF from ALF when the patient deteriorates becomes the relevant next step. The next time a MASLD patient with diabetes or significant obesity comes back with a FIB-4 score that puts you at ease, pause before filing it. The score may be right - or it may be hiding bridging fibrosis in the one patient subgroup where it consistently underperforms. Walk GastroAGI through the clinical details - age, metabolic comorbidities, FIB-4 result, VCTE availability - and get a structured, guideline-anchored next-step recommendation in seconds.

GastroAGI TeamRead more

6 min readMay 22, 202630reads

Hepatic Encephalopathy in 2026: What the New ACG Guideline Changes About How You Diagnose, Treat, and Prevent It

Your cirrhotic patient is confused. Ammonia is elevated. You start lactulose and order a CT head out of habit. If that sequence sounds familiar, the new ACG hepatic encephalopathy guideline - published in March 2026 - is going to make you rethink several of those reflexes. Here is what changed, what stayed the same, and what it means for the patient in front of you tonight. Hepatic encephalopathy remains one of the most clinical challenging complications of cirrhosis - not because the diagnosis is obscure, but because the spectrum from covert to overt disease is wider than most clinicians manage systematically. The 2026 ACG guideline is the first to consolidate diagnosis, inpatient management, recurrence prevention, nutrition, TIPS-related HE, and transplant access into a single GRADE-based framework. Before this guideline, most clinicians were working from fragmented guidance across AASLD, EASL, and institutional protocols. The 24 recommendations now provide a unified, evidence-ranked reference for the full clinical journey. This is not a marginal update. Several recommendations directly contradict common practice. Diagnosing Covert and Minimal HE: Stop Relying on Ammonia Alone The first section of the new hepatic encephalopathy guidelines 2026 deals with covert hepatic encephalopathy (CHE) and minimal hepatic encephalopathy (MHE) - the grades most frequently missed in clinic because patients do not look overtly encephalopathic. The guideline makes two important diagnostic moves here. First, it recommends a single-test strategy over a two-test combination when evaluating for MHE or CHE. This is a practical shift - it reduces the diagnostic burden without sacrificing sensitivity in most clinical settings. Second, and more consequentially, it explicitly recommends against using serum ammonia levels alone to make the diagnosis of MHE or CHE. This matters because ammonia is still reflexively ordered as a screening tool in many hepatology clinics. The guideline is clear: ammonia does not reliably differentiate covert from overt disease, and its level does not correlate consistently with HE grade. Clinicians should instead rely on validated neuropsychological testing tools - the Psychometric Hepatic Encephalopathy Score (PHES), the Animal Naming Test, or the EncephalApp Stroop test - depending on local availability. On treatment of MHE and CHE: the guideline suggests treatment with lactulose over no treatment, but acknowledges the evidence for preventing progression to overt HE remains insufficient to make a strong recommendation. In other words - treating covert HE is reasonable but not mandatory, and the decision should be individualized based on patient circumstances, driving status, occupation, and quality of life impact. Case in Point A 58-year-old male with Child-Pugh B cirrhosis from NASH presents for a routine follow-up. His family reports subtle personality changes over the past three months - slower responses, occasional confusion with dates, increased irritability. On examination he is oriented but takes noticeably longer to answer questions. Ammonia is 62 µmol/L - mildly elevated, but his baseline is unknown. His hepatologist administers the Animal Naming Test bedside - he names 11 animals in 60 seconds (below the age-adjusted threshold of 14). EncephalApp Stroop is borderline. He is diagnosed with covert hepatic encephalopathy. After discussion with the patient and his family, lactulose is initiated with a target of two to three soft bowel movements daily. At follow-up eight weeks later, his family reports meaningful improvement in cognitive sharpness. His driving status is reviewed and he continues to drive for now, with a plan to reassess. Inpatient Management: Two Recommendations That Should Change Your Workflow For overt HE presenting in the inpatient setting, the 2026 guideline makes its strongest recommendations. On ammonia testing during admission: The guideline recommends against routine serial serum ammonia monitoring to guide treatment decisions in overt HE. Ammonia does not track reliably with clinical response, and repeated testing adds cost without changing management. Lactulose titration should be guided by clinical response - stool frequency and mental status - not ammonia trajectory. On brain imaging: In a cirrhotic patient with confusion and no new-onset focal neurologic deficits, the guideline recommends against routine brain imaging. This does not mean CT head is never appropriate - it means it should not be a default order. If there are focal signs, new seizure activity, head trauma, or atypical features, imaging is indicated. Otherwise, it adds radiation and cost without diagnostic yield in classic HE. First-line treatment: Lactulose remains the recommended first-line therapy for overt HE, with a target of two to three soft bowel movements per day. The guideline introduces a notable alternative: high-volume polyethylene glycol (PEG) preparation - essentially a bowel prep - is now suggested as an option for patients who do not tolerate lactulose or where rapid gut clearance is the priority. Several trials have shown PEG to be non-inferior and in some cases faster-acting than lactulose for acute episodes. Rifaximin for TIPS: One of the most operationally specific recommendations in the entire guideline covers TIPS procedure management. The guideline recommends initiating rifaximin 14 days before elective TIPS insertion and continuing for at least six months post-procedure in patients with decompensated cirrhosis, regardless of prior HE history. It also suggests embolizing extrahepatic portosystemic collaterals at the time of TIPS to reduce post-TIPS HE risk. Both recommendations are concrete, time-specific, and immediately actionable. A Frequently Overlooked Point: The Transplant Access Gap for Recurrent HE Most hepatologists are aware that MELD score drives transplant listing. What the 2026 guideline addresses explicitly - and what rarely gets documented adequately - is that recurrent HE substantially impairs quality of life and cognitive function without necessarily elevating MELD to transplant-eligible thresholds. The guideline specifically notes that the progression from covert to overt HE is not adequately reflected in current transplant listing criteria, leaving patients undertreated for transplantation despite significant burden. For patients with multiple HE episodes and MELD below 15, the guideline suggests evaluating candidacy for living donor liver transplantation. This is a clinical pathway that should be discussed earlier and documented more consistently than it currently is in most hepatology practices. Bottom Line for Clinical Practice Do not use serum ammonia alone to diagnose MHE or CHE - use validated psychometric tools (PHES, Animal Naming Test, EncephalApp Stroop). Stop ordering routine brain CT in cirrhotic patients with confusion and no focal neurologic signs - it changes management only in atypical presentations. Stop following serial ammonia levels to track inpatient HE response - titrate lactulose to stool frequency and clinical mental status instead. PEG preparation is now a guideline-endorsed alternative to lactulose for acute overt HE - consider it when lactulose is not tolerated or rapid clearance is needed. Start rifaximin 14 days before elective TIPS and continue for at least six months - this applies even in patients with no prior HE history. Document HE burden explicitly in patients with MELD <15 and recurrent episodes - low MELD does not mean low disease burden, and living donor transplant candidacy should be discussed earlier. For a practical grading reference alongside this post, see Hepatic Encephalopathy: West Haven Grading, Identifying the Precipitant, and Step-by-Step Management . If SBP is on your differential as a precipitant, Spontaneous Bacterial Peritonitis: PMN Threshold, Antibiotic Selection, and Prophylaxis Protocol covers the full workup. And for the higher-stakes admission where the underlying liver disease is unclear, ACLF vs ALF: How to Tell Them Apart and Why It Changes Everything About Treatment is worth having open in parallel. When your next cirrhotic patient presents with confusion, or you are planning a TIPS procedure, or you are trying to decide whether to treat a patient whose family says "he just seems slower lately" - walk GastroAGI through the clinical details. It returns a guideline-anchored, case-specific response in seconds, so the 2026 ACG recommendations are applied to your actual patient, not just the textbook one. Try GastroAGI →

GastroAGI TeamRead more

6 min readMay 21, 202617reads

ESGE Days 2026 Milan: What Every Gastroenterologist Needs to Take Back to Practice

Over 5,000 endoscopists descended on Milan's Allianz MiCo Convention Centre from May 14–16 for what has become the most important GI endoscopy congress in Europe. Three days, 44 educational sessions, live endoscopy from the Humanitas University Medical School, landmark trial data, and a record-breaking abstract haul. If you weren't there - or if you were and couldn't see everything - here is the clinical substance that matters. ESGE Days 2026 marked a turning point in several areas simultaneously: the obesity space was shaken by a head-to-head comparison between endoscopic sleeve gastroplasty and oral semaglutide, new randomised data landed for Crohn's strictures and gastroparesis, and the society formally launched three Special Interest Groups that will define the agenda for the next decade. The breadth of the scientific programme - from yoga in the endoscopy unit to robotic ERCP - reflected just how rapidly the field is evolving. Not every session changes practice immediately, but several clearly will. The Headline Data: Bariatric Endoscopy Challenges the GLP-1 Era The single most-discussed finding from the congress was a comparative study presented on Friday, May 15, examining endoscopic sleeve gastroplasty (ESG) versus oral semaglutide for obesity. In 150 patients from routine clinical practice, ESG produced a mean total body weight loss of 12.7% at six months versus 8.7% with 14mg oral semaglutide - a 4.0% difference that was statistically significant (p=0.0001) and remained robust across multiple sensitivity analyses. The clinical implications extend beyond the numbers. At the 10% weight loss threshold - a marker associated with metabolic benefit - 70% of ESG patients responded versus 43% on semaglutide. At the 15% threshold, the gap widened dramatically: 36% for ESG versus just 7%. Adverse event profiles were comparable between groups, with no serious complications or mortality in either arm. Lead author Dr. Nitin Jagtap framed the data correctly: this is real-world comparative evidence, not a manufactured superiority trial. For patients asking "procedure or pill?", endoscopists now have data to anchor that conversation. This finding directly feeds into the broader EBMT (Endoscopy Bariatric and Metabolic Treatment) sessions at the congress, which positioned endoscopic bariatric therapy alongside pharmacotherapy rather than below it in the obesity management hierarchy. Case in Point: When the Algorithm Breaks Down A 48-year-old woman with a BMI of 37, type 2 diabetes, and previous failed pharmacotherapy was referred for obesity management. She was already on a GLP-1 analogue for six months with modest response - 6% weight loss - and her HbA1c had improved marginally. Her hepatologist flagged concurrent metabolic-associated steatotic liver disease (MASLD). The question posed to the MDT: escalate semaglutide dose, switch agent, or refer for ESG? The MDT opted for ESG. At six months post-procedure, her total weight loss was 14.3%, HbA1c had normalised, and liver enzyme trends had reversed. The decision rested not just on efficacy data but on the durability argument - ESG's mechanism is structural rather than appetite-dependent, and the new ESGE Days data suggests that patients who do not achieve ≥10% weight loss with GLP-1 agents may particularly benefit from an endoscopic approach. The ESGE Days data now provides the benchmarks to make that case explicitly. Trial Data That Shifts the Management of Crohn's and Gastroparesis Two practice-changing randomised controlled trials were featured in the ESGE Research Champions' Den - the congress's flagship research showcase, this year backed by a doubled grant pool of €50,000. The DECISION-CD study compared endoscopic stricturotomy against balloon dilation for short Crohn's disease strictures. This matters because balloon dilation has been the default for strictures under 4–5 cm, but recurrence rates at 12 months remain substantial. The stricturotomy data presented at ESGE Days 2026 will inform whether the next iteration of ESGE Crohn's guidelines shifts that default - a topic extensively debated in the dedicated session. The second RCT addressed one of the most contested debates in therapeutic endoscopy: G-POEM versus endoscopic balloon dilation for gastroparesis, covering idiopathic, post-surgical, and diabetic subtypes in a multicenter double-blind design. G-POEM has been gaining ground for refractory gastroparesis, and the randomised comparison data presented here will likely settle the head-to-head question that observational series never could. Both studies were presented alongside ESGE guideline sessions covering the same topics - a deliberate programme design that positioned trial data immediately within its clinical application framework. What Clinicians Commonly Underestimate: The Structural Shifts at This Congress The single most underreported story from ESGE Days 2026 is not a study - it's three launches. ESGE formally inaugurated Special Interest Groups (SIGs) in ESD, HPB Endoscopy, and Bariatric Endoscopy. These are not just networking forums; they are long-term collaborative structures that will generate ESGE position statements, training curricula, and quality benchmarks in subspecialty areas that have until now developed somewhat independently of central ESGE oversight. For endoscopists working in these areas, SIG membership in the coming year will be worth more than most CME activities - because it directly shapes the guidelines you will one day be asked to implement. The congress also premiered a new Multidisciplinary Team session format covering HPB oncology and colorectal neoplasia - a deliberate acknowledgment that endoscopic decision-making increasingly happens within MDT frameworks rather than in the endoscopy suite in isolation. Bottom Line for Clinical Practice ESG outperforms oral semaglutide at 6 months (12.7% vs 8.7% weight loss; 70% vs 43% achieving ≥10% loss) - this data supports positioning ESG as a first-line structural option rather than a fallback after pharmacotherapy failure. DECISION-CD and the G-POEM RCT are the two studies most likely to influence ESGE Crohn's and gastroparesis guidelines in the next 12–18 months - track the full publications in Endoscopy journal. Three new ESGE SIGs (ESD, HPB, Bariatric Endoscopy) launched at Milan - engagement now positions you at the frontier before these groups produce their first formal guidance documents. The Best Abstract Award went to six authors spanning Barrett's oesophagus (PREFER study low LNM recurrence data), post-ERCP pancreatitis prevention (FLUYT-2), and post-colonoscopy CRC detection - all three are worth a full read. Record abstract submissions and a fully sold-out hands-on training programme confirm ESGE Days' status as Europe's premier endoscopy meeting - abstracts will be published in Endoscopy (IF 12.8) and are available on-demand until July 31, 2026. ESGE Days comes once a year. The data presented in Milan this week will take 12–18 months to filter into guidelines and curricula. GastroAGI tracks all of it in real time - next time a Crohn's stricture or a bariatric referral lands on your list, run the case through GastroAGI for a guideline-anchored, up-to-date clinical response. Also read: DDW 2026 Highlights: Day-by-Day Conference Insights for Gastroenterologists People also read: APASL 2026 Istanbul: Key Clinical Takeaways Every Hepatologist Needs to Know

GastroAGI TeamRead more

6 min readMay 20, 202612reads

Obesity is Plateauing in the West and Accelerating Everywhere Else: What That Means for Clinical Practice

A 34-year-old woman from a Pacific Island nation presents with a BMI of 38, type 2 diabetes diagnosed two years ago, and a haemoglobin of 9.4 g/dL. She has visible signs of iron and B12 deficiency alongside frank visceral obesity. She is, in nutritional terms, both overnourished and undernourished simultaneously. This is not an edge case anymore - it is the clinical reality of obesity in 2026 across much of the low- and middle-income world, and treating only one half of the picture will fail the patient. The largest epidemiological analysis of obesity ever published - the NCD Risk Factor Collaboration's 2026 study in Nature , tracking 232 million individuals across 200 countries from 1980 to 2024 - does not just tell us where obesity is. It tells us how fast it is moving , and which populations are now past the inflection point. The findings have direct implications for how gastroenterologists and GI clinicians approach obesity-related disease in patients coming from different epidemiological backgrounds. The Velocity Data Changes the Conversation on Global Obesity Acceleration Prevalence statistics are a snapshot. Velocity - the year-on-year rate of change - is the leading indicator, and the NCD-RisC analysis treated it as the primary signal. In high-income Western nations, the story is essentially one of early alarms followed by a slow ceiling. The rise in childhood obesity began decelerating around 1990 and plateaued in most of these countries by the mid-2000s. Adults followed roughly a decade behind. Importantly, these plateaus do not represent the same level of harm. Girls in Japan, Denmark, and France plateaued at a childhood obesity prevalence of 3–4%. Boys in the United States plateaued at 23%. Adult prevalence among "plateaued" nations ranges from 11% in France to 25–43% in the UK, Canada, and the United States. A plateau is not a solution - it is a permanently elevated baseline from which metabolic disease, MASLD, and GI malignancy will continue accumulating for decades. In low- and middle-income countries (LMICs), the curve is still climbing. As of 2024, obesity prevalence was rising at more than 0.5 percentage points per year in 100 countries for women and 66 countries for men. The steepest accelerations are in Pacific Island nations, sub-Saharan Africa, and parts of South and Southeast Asia. Several of these trajectories have already surpassed the peak velocities ever recorded in the West. Per the NCD-RisC analysis, this is not simply the West's obesity story playing out on a time delay - the social and nutritional contexts are structurally different, which changes how the disease presents and how it should be managed. Clinical Scenario: The Dual-Burden Patient Who Doesn't Fit Standard Algorithms A 41-year-old man from a semi-urban area of sub-Saharan Africa presents to a tertiary centre with MASLD confirmed on fibroscan (liver stiffness 9.8 kPa), a BMI of 33, and a random blood glucose of 14.2 mmol/L. His dietary history reveals high refined carbohydrate intake, low protein, and near-zero dietary fat - not excess calories across the board, but a severe macronutrient imbalance. His albumin is 29 g/L. He has not eaten animal protein more than twice weekly throughout his life. Applying standard MASLD or obesity management guidelines - designed around a well-nourished, sedentary, calorically-replete Western patient - produced a recommendation for caloric restriction and a referral pathway toward GLP-1 therapy. The caloric restriction, without correcting protein and micronutrient deficiency first, worsened his sarcopenia and delayed glycaemic improvement. The clinical team course-corrected only after a dietitian flagged his MUAC and the discrepancy between his visceral fat burden and his lean mass. The case is a reminder that obesity management algorithms embedded in GI practice were not derived from patients carrying a simultaneous undernutrition burden. Managing Obesity Where Undernutrition Persists: What the Evidence Supports The dual burden of malnutrition - obesity coexisting with micronutrient deficiency and/or protein-energy undernutrition - is now formally recognised by the WHO and FAO as a distinct nutritional phenotype, most common in urban populations in LMICs undergoing rapid dietary transition. For gastroenterologists, this matters in at least three clinical scenarios: pre-bariatric surgery assessment, MASLD management, and nutritional rehabilitation after GI illness. In bariatric surgery candidates from high-velocity obesity regions, pre-operative nutritional assessment needs to go beyond BMI and standard metabolic panels. Thiamine, iron, folate, B12, zinc, and vitamin D deficiencies are prevalent at baseline in LMIC populations seeking bariatric intervention - and post-surgical malabsorption compounds what is already an under-repleted reserve. A 2023 systematic review in Obesity Reviews found that pre-operative micronutrient deficiency rates in LMICs were consistently two to three times higher than in matched Western bariatric cohorts. This is not a contraindication to surgery; it is an argument for a minimum 3-month nutritional optimisation window before any bariatric procedure, and for extending post-operative supplementation protocols. In MASLD, the dual-burden phenotype often presents with a pattern of hepatic steatosis without the dyslipidaemia pattern typical of Western patients. Triglycerides may be near-normal; LDL unremarkable. The driver is hyperinsulinaemia from refined carbohydrate load combined with insufficient dietary protein to support hepatic lipid export. Management here prioritises protein adequacy and glycaemic index modification over aggregate caloric reduction - a subtle but important distinction from standard MASLD dietary guidance. Where GLP-1 receptor agonists are unavailable or unaffordable - which describes most of the 100 countries still in the obesity acceleration phase - realistic interventions lean on dietary modification, structured physical activity, and treating the undernutrition component as a prerequisite rather than an afterthought. The evidence base for metformin as an adjunct in this population remains robust and affordable. A Frequently Overlooked Point: "Plateau" Does Not Mean Harm Has Stopped There is a tendency in clinical practice to view plateaued obesity prevalence in high-income countries as a policy success story. The NCD-RisC data complicates this. A plateau at 40% adult obesity - as in the United States - still means a relentlessly expanding pool of patients with MASLD, cirrhosis, oesophageal adenocarcinoma, and colorectal cancer. The lag between obesity prevalence and GI malignancy incidence runs to 10–20 years. Countries that plateaued in the early 2000s are now entering the peak period for those downstream consequences. Gastroenterologists in both plateaued and accelerating countries will be managing more obesity-attributable GI disease, not less, for the next two decades regardless of what prevention programmes achieve. Bottom Line for Clinical Practice Screen dual-burden nutritional status explicitly in any obese patient from a high-velocity obesity region or LMIC background - do not assume obesity equals nutritional sufficiency. Albumin, MUAC, and a targeted micronutrient panel (thiamine, B12, iron, zinc, D) should be standard. Pre-bariatric nutritional optimisation matters more, not less, in LMIC-origin patients - a minimum 3-month correction window for identified deficiencies before surgery, with extended post-operative supplementation protocols. In MASLD with dual-burden phenotype, prioritise protein adequacy and glycaemic index reduction over aggregate caloric restriction; the steatosis driver is macronutrient imbalance, not pure caloric excess. Plateau in high-income countries does not reduce GI disease burden - the lag between obesity prevalence and downstream GI malignancy means colonoscopy demand, MASLD progression cases, and oesophageal cancer referrals will continue rising in plateaued nations well into the 2030s. Where GLP-1 agents are unavailable , structured dietary protein rehabilitation combined with metformin and glycaemic index-targeted dietary advice represents the most evidence-supported accessible pathway for the dual-burden obese patient. When a case like this lands in front of you - obesity with concurrent nutritional deficiency, an atypical MASLD lipid profile, or a pre-bariatric patient from a high-velocity obesity region - walk GastroAGI through the clinical details. It will apply the relevant nutritional and GI evidence to your specific patient, not the textbook average. Read More on: Obesity Pharmacotherapy in 2026: How EASO's Complication-First Framework Changes the Way You Choose a Drug

GastroAGI TeamRead more

7 min readMay 18, 202616reads

Obesity Pharmacotherapy in 2026: How EASO's Complication-First Framework Changes the Way You Choose a Drug

Your patient has a BMI of 34, MASLD on ultrasound, and an HbA1c of 6.8%. You reach for a GLP-1 - but which one? For what endpoint? And what counts as treatment success? Until recently, the default answer was "the one that causes the most weight loss." The EASO 2026 framework formally dismantles that logic. For years, obesity pharmacotherapy was weight-loss pharmacotherapy. The primary endpoint was kilograms - and the drug hierarchy followed suit. That framing missed something fundamental: the patient sitting across from you doesn't have "obesity." They have sleep apnoea worsening their hypertension, or knee pain preventing them from exercising, or steatohepatitis quietly progressing toward cirrhosis. The EASO 2026 update on obesity pharmacotherapy makes explicit what many experienced clinicians already suspected - the right drug depends entirely on the complication you are trying to reverse, not on BMI alone. This reframing matters particularly for gastroenterologists and hepatologists. Obesity is not a background variable in MASLD, MASH, or metabolic-associated liver disease. It is often the primary driver. The 2026 framework now positions liver disease endpoints - MASH remission and fibrosis improvement - as legitimate treatment targets for obesity-management medication (OMM), with drug-specific evidence mapped to each endpoint. The Mechanical vs Metabolic Divide: Why Your Endpoint Changes Everything in Obesity Pharmacotherapy The EASO 2026 framework divides obesity complications into two mechanistic categories, and this division is clinically operational - not just taxonomic. Mechanical adiposity refers to complications driven by excess physical mass: obstructive sleep apnoea syndrome (OSAS) from pharyngeal fat deposition and reduced chest wall compliance, and knee osteoarthritis (KOA) from increased joint load. The treatment target here is mechanical unloading - weight loss that reduces physical forces. In OSAS, the goal is remission; in KOA, it is pain remission and improved mobility. Metabolic adiposity covers the broader cardiometabolic and hepatic spectrum: prediabetes, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure with preserved ejection fraction, MASLD, MASH, and liver fibrosis. Here the pathophysiology involves adipokine dysregulation, ectopic fat deposition, insulin resistance, systemic inflammation, and direct lipotoxicity. Weight loss helps - but the ideal drug also targets the tissue-level pathology, not only the scale. Per the EASO 2026 update, the clinical question to ask before prescribing is no longer "What is the BMI?" but "What complication am I treating, and what endpoint defines success?" This is a structural shift in how obesity is managed - from a single-axis disorder to a complication-specific disease requiring the same endpoint-driven logic as hypertension or dyslipidaemia. The drug hierarchy follows directly from this. Tirzepatide leads for total body weight loss. Semaglutide has the broadest complication-specific evidence across cardiovascular disease (MACE reduction via SELECT), MASLD/MASH, prediabetes, knee OA, heart failure, and - crucially - liver fibrosis improvement. These are not interchangeable drugs prescribed for interchangeable reasons. Clinical Scenario: MASLD with Obesity - When "Lose Weight" Is Not a Complete Order A 51-year-old woman presents with a 3-year history of MASLD on ultrasound. Her BMI is 33.4. She has prediabetes (HbA1c 6.4%), mild dyslipidaemia, and no prior cardiovascular events. Her liver stiffness on FibroScan is 7.2 kPa. She has tried lifestyle modification twice - each time losing 6–8 kg and regaining it within a year. She is started on semaglutide 2.4 mg weekly, with the explicit treatment targets stated at initiation: normalisation of glycaemia, liver enzyme improvement, and - as fibroscan is repeated at 12 months - a reduction in liver stiffness as a proxy for fibrosis regression. At 14 months, HbA1c is 5.7%, she has lost 11% total body weight, and her liver stiffness has decreased to 5.8 kPa. The distinction here matters operationally. If weight loss alone were the endpoint, a 10% reduction might be framed as a partial success. Framed instead as MASH remission and fibrosis stabilisation in a patient at risk of progression, it is a clinically meaningful disease-modifying outcome - and it changes how you counsel the patient on long-term continuation. Read more about NAFLD & MASH Treatment: https://gastroagi.com/blog/nafld-nash-treatment-resmetirom Semaglutide, Tirzepatide, and the Rest: Mapping Drug Evidence to Liver and Cardiometabolic Endpoints For gastroenterologists, the liver-specific evidence is now actionable. The EASO 2026 framework identifies semaglutide as the drug with current evidence for both MASH remission and liver fibrosis improvement - the latter categorised explicitly as a 2026 update, reflecting emerging data from the NASH trials and the ESSENCE trial programme. Tirzepatide, despite its superior weight-loss efficacy, does not yet carry mapped evidence for the fibrosis endpoint in the EASO framework. This has a practical implication: in a patient with obesity and biopsy-proven or fibroscan-confirmed significant fibrosis (≥F2), semaglutide at obesity dosing (2.4 mg weekly) is the better-evidenced choice at present - even if tirzepatide might produce greater weight loss. The treatment target is the liver, not the scale. For the cardiovascular endpoint (MACE reduction), semaglutide again holds the evidence - the SELECT trial demonstrated a 20% reduction in MACE in patients with obesity and established cardiovascular disease, without diabetes as an entry requirement. This was a landmark shift: cardiovascular protection from an obesity drug independent of glycaemic benefit. Tirzepatide leads for total body weight loss (SURMOUNT-1: ~20% TBWL at 72 weeks) and has emerging evidence for OSAS remission, making it the preferred agent when maximal weight reduction is the dominant goal - particularly in patients with severe obesity, high surgical risk, or those being optimised prior to bariatric procedures. For heart failure, both tirzepatide (SUMMIT) and semaglutide carry evidence for hospitalisation reduction in obese HFpEF patients - a population that represents a growing proportion of heart failure admissions in South Asian practices. Liraglutide remains relevant at 3 mg daily, particularly for knee osteoarthritis pain remission and as a lower-cost incretin option in prediabetes - but it is no longer the leading agent for most metabolic endpoints. Older agents (orlistat, naltrexone-bupropion, phentermine-topiramate) retain narrower roles: phentermine-topiramate contributes to weight loss but lacks complication-specific evidence for most organ endpoints. A Frequently Overlooked Point: Framing the Endpoint Before You Write the Prescription The most underused step in obesity pharmacotherapy is stating the treatment target explicitly before initiating the drug - not to the patient's BMI, but to their dominant complication. This matters because it defines what success looks like at 6 months, determines when to escalate or switch, and - critically - strengthens the clinical justification for long-term continuation in systems where cost or formulary access requires documented medical necessity. A patient whose treatment goal is "MASH remission and fibrosis stabilisation" has a different monitoring plan (LFTs, fibroscan, MRE at 12 months) than a patient whose goal is "MACE risk reduction" (lipid panel, blood pressure, event-free survival). Both may be on semaglutide. Both are treated for obesity. The drug is the same; the clinical logic is not. Bottom Line for Clinical Practice Do not anchor drug selection to BMI alone. The EASO 2026 framework requires identifying the dominant complication first - MASLD/MASH, cardiovascular disease, heart failure, OSAS, prediabetes, or T2DM - and selecting the agent with outcome evidence for that endpoint. For MASH remission and liver fibrosis improvement, semaglutide currently has the strongest mapped evidence. Tirzepatide produces superior weight loss but lacks equivalent fibrosis endpoint data in the 2026 framework. For MACE reduction in obesity without diabetes, semaglutide is the drug with trial evidence - the SELECT trial established this independently of glycaemic benefit. Tirzepatide leads for total body weight loss and is the preferred agent when maximal weight reduction is the primary goal - including pre-bariatric optimisation or severe obesity with OSAS. State the treatment target explicitly at initiation - endpoint, monitoring interval, and definition of response. This changes counselling, follow-up planning, and the case for long-term continuation. When your next patient with MASLD and obesity sits across from you, the question is no longer which drug helps them lose the most weight. It is which drug best targets their liver - and what endpoint confirms it is working. GastroAGI can walk through the clinical details with you in real time: complication profile, drug mapping, monitoring intervals, and the evidence behind each decision.

GastroAGI TeamRead more

6 min readMay 13, 2026354reads

H. pylori Treatment in 2026: Choosing the Right First-Line Regimen When Clarithromycin Is No Longer the Default

Your patient tests positive for H. pylori - straightforward PPI + clarithromycin + amoxicillin, right? Not anymore. Clarithromycin resistance has crossed 15–20% in most urban centres, and PPI triple therapy now fails in roughly one in four patients before you even factor in CYP2C19 metabolism. The 2026 ACG guideline has moved the goalposts on first-line treatment, and if you're still reaching for the old triple automatically, this post is for you. The clinical problem isn't diagnosing H. pylori - it's eradicating it on the first attempt. Each failed treatment course selects for resistance, narrows your future options, and increases the patient's cumulative antibiotic exposure. The 2026 ACG Clinical Guideline (summarised in the March 2026 edition of JAMA) marks a decisive shift: PPI triple therapy is no longer the preferred first-line option except in specific, guideline-defined circumstances. The new defaults are bismuth quadruple therapy (BQT) and vonoprazan (PCAB)-based regimens - both achieving eradication rates above 85–90% even in the setting of clarithromycin resistance. Understanding when to use each, and why the old approach underperforms, is now a core competency for any clinician managing upper GI disease. Why Bismuth Quadruple Therapy Has Become the Standard First-Line Approach BQT - a PPI twice daily plus bismuth subcitrate (120–300 mg) or subsalicylate (300 mg) four times daily, tetracycline (500 mg) four times daily, and metronidazole (500 mg) three or four times daily for 14 days - achieves eradication rates of 85–95% in treatment-naive patients regardless of clarithromycin or metronidazole resistance status. This is the key point: BQT does not depend on clarithromycin sensitivity. Bismuth exerts a direct bactericidal effect on H. pylori at the mucosal surface, independent of antibiotic susceptibility testing, which is why it outperforms PPI triple therapy across resistance profiles. Per the 2026 ACG guideline, BQT is recommended as a preferred first-line regimen for treatment-naive patients in the United States, where clarithromycin resistance rates exceed the 15% threshold that consistently degrades triple therapy outcomes. The 14-day course is not optional - shorter durations reduce eradication rates by 5–10 percentage points. The practical barrier is pill burden: patients take 14–16 tablets daily, which requires explicit counselling upfront. Adherence, not drug potency, becomes the rate-limiting factor. Set expectations at the first prescription: explain the schedule, name the likely side effects (bismuth black stools, mild nausea), and confirm there's no penicillin allergy before prescribing amoxicillin in any multi-drug regimen. One secondary consideration worth noting: tetracycline resistance in H. pylori is rare globally, making BQT remarkably durable even as other antibiotic resistance patterns shift. In the absence of local susceptibility data - the reality for most outpatient gastroenterology practices - BQT is the most defensible empirical choice. Clinical Scenario A 38-year-old woman presents with a 4-month history of epigastric pain and early satiety. Endoscopy reveals a non-bleeding duodenal ulcer; rapid urease test is positive for H. pylori . She has no known drug allergies. Her GP had previously prescribed a 7-day PPI triple therapy course two years ago for "gastritis," and she reports she completed it - but was never tested for eradication. Treatment with BQT (bismuth subcitrate 240 mg four times daily, tetracycline 500 mg four times daily, metronidazole 500 mg four times daily, omeprazole 20 mg twice daily) was initiated for 14 days. Urea breath test at 6 weeks post-treatment confirmed eradication. The clinical lesson here isn't just about regimen selection - it's about recognising prior treatment as a resistance risk factor. A patient with a previous failed or unconfirmed course should not receive PPI triple therapy empirically. BQT or susceptibility-guided therapy is the appropriate choice, and test-of-cure is mandatory after any eradication attempt. Vonoprazan-Based Regimens: Where They Fit and When to Choose Them Vonoprazan (a potassium-competitive acid blocker, or PCAB) represents a genuinely new mechanism in H. pylori treatment. Unlike PPIs, vonoprazan achieves near-complete acid suppression within hours and maintains it irrespective of CYP2C19 genotype - the pharmacokinetic variability that explains why "slow metabolisers" tolerate PPIs well but "rapid metabolisers" produce insufficient acid suppression and undermine antibiotic efficacy. The 2026 ACG guideline endorses two vonoprazan-based regimens for treatment-naive patients: PCAB dual therapy: Vonoprazan 20 mg twice daily + amoxicillin 1000 mg three times daily for 14 days PCAB triple therapy: Vonoprazan 20 mg + clarithromycin 500 mg + amoxicillin 1000 mg twice daily for 14 days PCAB dual therapy is particularly useful when metronidazole resistance is a concern or when minimising total antibiotic load is a priority. It delivers eradication rates of 80–87% in clinical trials, with a simpler dosing schedule than BQT. PCAB triple therapy performs comparably to BQT in clarithromycin-susceptible patients but loses its edge when clarithromycin resistance is present. The cost differential matters in many healthcare systems: vonoprazan is significantly more expensive than generic bismuth-tetracycline combinations, which may influence formulary decisions in resource-sensitive settings. Rifabutin triple therapy (omeprazole 40 mg + amoxicillin 1000 mg + rifabutin 50 mg, all three times daily for 14 days) remains a guideline-endorsed option - particularly relevant for patients with penicillin intolerance requiring alternative backbones - but its use should be weighed against the risk of Mycobacterium resistance given rifabutin's role in TB regimens. A Frequently Overlooked Point: Test-of-Cure Is Not Optional The most common gap in H. pylori management in clinical practice is not regimen selection - it's the failure to confirm eradication. The 2026 ACG guideline and prior ACG/AGA consensus are explicit: all patients treated for H. pylori should undergo test-of-cure at least 4 weeks after completing antibiotics and at least 2 weeks after stopping PPIs. The urea breath test and stool antigen test are both acceptable; serology is not. In patients with peptic ulcer disease or a family history of gastric cancer, eradication confirmation is not a courtesy - it is the clinical endpoint. Missing this step leaves you with a patient who believes they've been treated while carrying viable, now-resistant H. pylori , and a chart that offers no guidance when they return symptomatic in 18 months. Bottom Line for Clinical Practice Stop defaulting to PPI triple therapy as empirical first-line treatment. Clarithromycin resistance rates in most urban populations now exceed the 15% threshold below which triple therapy is defensible. BQT for 14 days is the most robust empirical regimen for treatment-naive patients - resistance-independent and well-validated across populations. Vonoprazan dual or triple therapy is a guideline-endorsed alternative with simpler dosing; particularly useful when CYP2C19 variability or metronidazole resistance is a concern. Any prior treatment course, even one claimed to be completed , should prompt susceptibility-guided therapy or a switch to BQT - not re-prescription of triple therapy. Confirm eradication with UBT or stool antigen at least 4 weeks post-antibiotics and 2 weeks post-PPI in every patient, without exception. The next time you're standing at the prescription pad deciding between these regimens, walk GastroAGI through the case - prior treatment history, allergy status, local resistance patterns - and get a guideline-anchored recommendation in seconds. And if you're managing H. pylori in an Indian clinical context, read our deep-dive on H. pylori Treatment Guidelines in India - local resistance data, regimen availability, and what the evidence actually supports in your practice setting.

GastroAGI TeamRead more

11 min readMay 11, 202626reads

DDW 2026 Highlights: Day-by-Day Conference Insights for Gastroenterologists

You couldn't be everywhere at DDW 2026. Four days, hundreds of sessions, thousands of attendees across McCormick Place - and the signal-to-noise ratio was unforgiving. This post cuts straight to what mattered: the clinical themes that surfaced repeatedly, the practice-changing debates, and the takeaways that will follow you into clinic long after the Chicago wind fades. Day by day. What DDW 2026 Was Really About Digestive Disease Week 2026 (May 2–5, Chicago) arrived at an inflection point for the specialty. EUS has graduated from a diagnostic tool to a full therapeutic platform. Endoscopy is being reimagined as a surgical discipline. Gut-brain interaction disorders finally got the mechanistic attention they deserved. And for the first time, artificial intelligence wasn't a background conversation - it was embedded in imaging, diagnostics, and clinical decision-making across almost every sub-track. The DDW 2026 gastroenterology agenda reflected a field in genuine transition. The dominant clinical questions were no longer "can we do this endoscopically?" - that debate is largely settled. The harder questions now are: when should we, how do we train for it, and what does value-based care look like when a GI suite can now do what once required an OR? Here is how it unfolded. Day 1 (May 2): Pancreatitis, Pancreatic Cysts, and EUS as the New Standard The Anchor Topic: Acute Pancreatitis in 2026 Day 1 opened with a strong focus on acute pancreatitis modern management — and the message was clear: the 2024–2025 guideline updates are still not being fully implemented at the bedside. DDW 2026 re-emphasized that fluid resuscitation strategy (Lactated Ringer's over normal saline), early oral feeding in mild disease, and avoidance of prophylactic antibiotics remain systematically underutilized. Severity prediction — still the crux of the first 48 hours — was presented through emerging AI-assisted scoring models that integrate SIRS criteria, BUN trajectory, and hematocrit trends more dynamically than static scoring tools like BISAP or Ranson's. Necrotizing pancreatitis management continued to draw debate. The "step-up" approach remains standard, but Day 1 sessions highlighted how EUS-guided drainage of walled-off necrosis is consolidating as the preferred first intervention over percutaneous routes at centers with the expertise — with lower rates of pancreatic fistula formation and shorter hospital stays. Pancreatic Cysts: Rethinking Both Detection and Surveillance Two separate sessions tackled pancreatic cyst management from complementary angles. The first examined surveillance strategy - specifically, the clinical problem of the vast majority of detected cysts (the majority of which are incidentalomas on cross-sectional imaging) never progressing, yet consuming enormous surveillance resources. The emerging consensus leans toward risk-stratified, time-limited surveillance with clear exit criteria, rather than indefinite annual MRI. The second session pushed beyond fluid analysis: multimodal EUS assessment using AI-enhanced imaging, through-the-needle biopsy, and cyst fluid proteomics is improving discrimination between mucinous and non-mucinous lesions. The clinical takeaway - fluid CEA alone is insufficient. A high-risk mucinous cyst with low CEA is not a low-risk cyst. Clinical Scenario A 67-year-old woman with a 3.2 cm branch-duct IPMN detected incidentally on CT for renal colic. No worrisome features on initial MRI. CEA in cyst fluid: 38 ng/mL. She has been on annual MRI surveillance for four years, with stable morphology. At DDW 2026 sessions, this case was presented as exactly the type where newer multimodal EUS - incorporating confocal laser endomicroscopy and next-generation cyst fluid molecular markers - could support a shared decision to exit surveillance in a low-risk profile, rather than committing to indefinite follow-up with its costs, patient anxiety, and incidental findings. The question being asked at DDW is no longer "do we watch this?" but "how long, with what, and when do we stop?" Day 2 (May 3): EUS Expands, IBD Gets Structural, Endoscopy Meets Surgery EUS: From Diagnosis to Therapeutic Platform Day 2 consolidated EUS's place as one of the fastest-evolving areas in gastroenterology. Four distinct themes ran through EUS-focused sessions: EUS-guided biliary drainage (EUS-BD) was presented as a genuine first-line alternative to ERCP in select patients - not merely a rescue strategy for failed cannulation. The evidence base supporting EUS-hepaticogastrostomy and EUS-choledochoduodenostomy has matured enough that several centers are now offering EUS-BD as primary drainage in distal malignant obstruction with favorable anatomy. DDW 2026 sessions stressed that this shift requires operator volume, structured training, and outcome benchmarking - the technique is not interchangeable with ERCP in the hands of the occasional user. EUS in chronic pancreatitis was reframed as a therapeutic decision-support tool - not just for parenchymal/ductal assessment, but for guiding celiac plexus interventions and staging severity in ways that influence whether a patient is routed to ERCP, surgery, or pain-focused medical management. Interventional EUS in the lower GI tract - EUS-guided drainage of pelvic collections, perirectal abscesses, and anastomotic leaks - was positioned as an expanding clinical service with meaningful implications for post-surgical GI care. EUS as a high-value service was addressed specifically in an economics-focused session: as EUS procedure volumes grow and payer scrutiny intensifies, demonstrating diagnostic yield, procedure pairing efficiency, and downstream decision impact is no longer optional for program sustainability. Crohn's Strictures: Bowel Preservation as the Explicit Goal IBD surgery at DDW 2026 centered on Crohn's disease stricture management, with an unmistakable thematic shift: bowel-preserving therapy is now the stated goal, not simply a preference. Endoscopic balloon dilation, EUS-guided stricturoplasty, and biodegradable stenting were all presented with updated outcome data. The DDW 2026 consensus framing was that surgery should follow a failed endoscopic attempt, not precede it, for most short fibrotic strictures. Multidisciplinary decision-making - gastroenterologist, colorectal surgeon, and radiologist - was emphasized as the standard of care, not the exception. Day 3 (May 4): Esophageal Disorders, Motility, Obesity, and the Gut-Brain Axis Esophageal Disease: From POEM Complications to Barrett's Day 3 opened with a clinically rich esophageal surgery session. Recurrent dysphagia after POEM was examined with nuance - distinguishing incomplete myotomy from reflux-related stricture from functional post-procedural dysmotility. The diagnostic reassessment algorithm presented included timed barium swallow, high-resolution manometry re-evaluation, and pH-impedance testing on and off PPI before any re-intervention decision. Post-EMR bleeding risk stratification received a dedicated session, with updated scoring tools that integrate lesion size, morphology, location, and patient anticoagulation status to stratify risk more precisely than older approaches. DDW 2026 data suggested prophylactic clipping strategy should be tailored to risk category rather than applied uniformly. Deep mural injury versus true perforation after esophageal dilation was presented as a consistently mismanaged clinical scenario — the instinct to escalate to surgery for a large air collection without clinical deterioration is often wrong, and updated management algorithms favor conservative endoscopic closure with NPO and IV antibiotics for selected transmural injuries. Barrett's esophagus with low-grade dysplasia was given a focused session: surveillance intervals, endoscopic eradication therapy (EET) timing, and the emerging data supporting earlier EET in confirmed LGD on expert pathology review. Motility: FLIP Panometry Changes the Conversation Translational physiomechanics and FLIP panometry was one of the more intellectually dense Day 3 sessions. The key clinical message: conventional high-resolution manometry frequently fails to explain patient symptoms in functional dysphagia and non-obstructive dysphagia. FLIP panometry - measuring distensibility and contractile response - identifies clinically significant esophagogastric junction dysfunction that HRM misses. DDW 2026 presenters argued that FLIP should move from a supplementary to an integrated first-line tool in esophageal motility evaluation, particularly in post-fundoplication or post-POEM symptom recurrence. Obesity and Metabolic Endoscopy: A Specialty of Its Own The metabolic track at DDW 2026 was arguably the highest-energy programming of the conference. Metabolic surgery was presented through a long-term outcomes lens: 10+ year data from RYGB and sleeve gastrectomy cohorts confirmed durable T2DM remission and cardiovascular risk reduction, but also highlighted the significant subset with weight recurrence and metabolic relapse requiring reintervention. The integrated care model - bariatric surgery plus GLP-1 receptor agonist therapy plus psychological support was presented as the new standard. Endoscopic bariatric therapy (EBT) , and specifically endoscopic sleeve gastroplasty (ESG) - received major airtime. ESG is now the most widely performed EBT procedure globally, and DDW 2026 data presented weight loss outcomes at 18-24 months that are competitive with sleeve gastrectomy in appropriately selected patients. The discussion shifted from "does ESG work?" to "who is the optimal ESG candidate, and how do we integrate it with pharmacotherapy?" Metabolic endoscopy as a subspecialty designation - distinct from bariatric surgery is a DDW 2026 conversation that will have structural implications for GI training programs. Gut-Brain Axis: Finally Getting the Mechanistic Attention It Deserves Functional dyspepsia and gastroduodenal disorders were presented in two separate sessions - one focused on evolving gut-brain and immune paradigms, one on overlapping clinical presentations. The mechanistic picture now includes duodenal eosinophilia, mast cell activation, impaired mucosal barrier function, and altered central pain processing - none of which are captured in Rome IV criteria. DDW 2026 signaled that the diagnostic and treatment approach to functional dyspepsia is about to change substantially as these mechanisms become treatable targets. Nutritional interventions in DGBI - covering diet, microbiome, and gut-brain interaction - were presented with updated evidence on low-FODMAP diet implementation, specific carbohydrate diet, and probiotic stratification. POTS, hEDS, and gut dysmotility emerged as an increasingly recognized clinical cluster, with DDW 2026 sessions flagging that GI symptoms in these patients are frequently misattributed to functional disorders, delaying appropriate connective tissue-oriented workup. Day 4 (May 5): Screening, Training, Economics, and the Future of Endoscopy CRC Screening: Expanding Access Without Losing Precision The colorectal cancer screening track on Day 4 tackled a genuinely complex landscape. Stool-based testing integration - specifically FIT and multi-target stool DNA - was examined in the context of screening uptake gaps. Despite strong guideline endorsement, CRC screening rates remain suboptimal in low-resource and underserved settings. DDW 2026 presented primary care-GI integration models and patient navigation strategies that meaningfully improve uptake. The clinical message: the best screening test is the one the patient will actually do. Blood-based CRC screening (cell-free DNA and methylation-based assays) received a dedicated session examining where these tests fit in the clinical pathway. Sensitivity for CRC is strong; sensitivity for advanced adenoma remains the limiting factor. DDW 2026 framing: blood-based tests expand access and are appropriate for screening-reluctant patients, but positive results require colonoscopic confirmation and negative results do not replace colonoscopy for high-risk individuals. CRC in India was addressed in a separate global health session - highlighting distinct epidemiological features, delayed presentation, limited surgical infrastructure, and the opportunity for endoscopy-led early detection strategies in a rapidly urbanizing, high-risk demographic. Endoscopy Education: Competency-Based Training is Now the Standard Two full sessions addressed the transformation of endoscopy training, and both sent the same message: the apprenticeship era is over. Competency-based medical education (CBME) in endoscopy - using simulation, structured feedback, EHR-integrated quality metrics, and direct observation tools - was presented as the new training architecture. The fellow's perspective session was particularly pointed: current trainees are graduating into practice environments with volume-based expectations that competency-based training programs have not yet fully aligned with. Mastering endoscopy education focused on how high-volume, high-complexity programs (ESD, EUS, POEM, ESG) require purpose-built curricula that traditional case-number milestones cannot capture. DDW 2026's message to training program directors: redesign around skill acquisition curves, not case counts. Economics and Service Line Design The closing economics track was one of the more practical DDW 2026 contributions for program leadership. Expanding gastroenterology service lines in an era of declining procedural reimbursement, healthcare consolidation, and payer scrutiny requires GI practices to demonstrate clinical value - not just volume. Panelists presented models for quality dashboard integration, downstream referral capture, and EHR-anchored outcomes reporting as tools for payer contract negotiation. The colonoscopy quality dashboard session specifically showed how EHR analytics can drive system-level improvement in adenoma detection rates, withdrawal times, and bowel prep quality across a multi-site practice. The Four Overarching Themes of DDW 2026 Stepping back from the day-by-day: four themes ran through almost everything at DDW 2026. 1. EUS is a therapeutic subspecialty now. Biliary drainage, pancreatic cyst ablation, lower GI interventions, chronic pancreatitis management - EUS is not an add-on to endoscopy. Programs without structured EUS training pipelines are already behind. 2. Gut-brain interaction is mechanistically tractable. Functional dyspepsia, IBS, DGBI overlapping disorders, POTS/hEDS - the days of "nothing structural, reassure the patient" are ending. The pathophysiology is being defined, and treatable mechanisms are being identified. 3. AI is embedded, not emerging. AI-integrated EUS imaging, colonoscopy quality analytics, pancreatic cyst characterization, and CRC screening pathway optimization were not featured as "future" tools. They were presented as current clinical applications being implemented now. 4. Training must catch up to the procedures. ESG, ESD, POEM, EUS-BD - these are complex interventional skills. DDW 2026 sent an unambiguous message: competency-based training frameworks, simulation curricula, and structured mentorship models are not optional for programs offering these services. A Frequently Overlooked Point from DDW 2026 The sessions on ERCP in elderly patients with choledocholithiasis - specifically the target trial emulation data re-examining early ERCP - deserve attention beyond the conference. The conventional teaching that all common bile duct stones require early ERCP is being challenged by real-world data showing that appropriately selected elderly patients with uncomplicated choledocholithiasis and no cholangitis or pancreatitis can be managed with watchful waiting followed by elective ERCP, without increased adverse events. In a population already carrying high sedation risk, this is clinically important. The reflex to scope within 24 hours in every elderly patient with a stone should be reconsidered. Stay Current Without the Conference DDW runs for four days. The literature that follows it runs for four years. GastroAGI tracks emerging evidence across pancreatology, advanced endoscopy, IBD, hepatology, and motility disorders - and brings it into real clinical questions. Walk GastroAGI through a post-DDW clinical scenario: the next complex EUS case, the pancreatic cyst you're not sure whether to keep watching, the functional dyspepsia patient who has failed two PPI trials. You'll get a reasoned, guideline-anchored response built from the same evidence base that drove the conversations in Chicago.

GastroAGI TeamRead more

6 min readMay 8, 202622reads

Daraxonrasib in Previously Treated RAS-Mutated Pancreatic Cancer: What the NEJM Phase 1/2 Data Actually Means

A 61-year-old woman with metastatic pancreatic ductal adenocarcinoma has progressed through FOLFIRINOX. Her KRAS mutation is G12D - not G12C, which means sotorasib and adagrasib are off the table. Until recently, your only option was nanoliposomal irinotecan plus 5-FU or enrollment in a clinical trial, with an expected median overall survival of five to seven months. The Phase 1/2 daraxonrasib trial published in the New England Journal of Medicine in May 2026 changes the calculus. The second-line treatment landscape for pancreatic ductal adenocarcinoma (PDAC) has been defined by futility for decades. Fewer than 10% of patients respond to second-line chemotherapy, and median survival after progression on first-line therapy sits at five to seven months. KRAS inhibitors disrupted this ceiling in lung cancer, but pancreatic cancer posed a harder problem - the mutations are different, they're more heterogeneous, and KRAS drives PDAC in its active, GTP-bound "on" state rather than the inactive state targeted by earlier inhibitors. Daraxonrasib is the first RAS(ON) multi-selective inhibitor to enter clinical trials for PDAC, and the results out of this first-in-human trial represent the most credible survival signal this disease has seen in a very long time. Why Conventional KRAS Inhibitors Don't Work in PDAC - and How Daraxonrasib Is Different The oncology world celebrated sotorasib and adagrasib as breakthroughs in KRAS G12C-mutant lung cancer, but their application to pancreatic cancer was always going to be limited. KRAS G12C is relatively rare in PDAC - the dominant mutations are G12D, G12V, and G12R, none of which are addressed by those covalent inhibitors. More fundamentally, those agents work by locking KRAS in its inactive GDP-bound state. In PDAC, RAS proteins spend most of their time in the GTP-bound "on" state, actively driving tumor growth, which means the standard inhibitor mechanism has minimal traction. Daraxonrasib functions as a molecular glue: in combination with cyclophilin A, it blocks the signaling of RAS proteins in their active state. It is multi-selective - capable of targeting multiple RAS variants, including G12D, G12V, and G12R - which matters enormously in a disease where mutation heterogeneity has historically made targeted therapy nearly impossible. More than 90% of pancreatic adenocarcinomas are driven by RAS mutations, meaning the theoretical addressable population for this mechanism is the entire PDAC population, not a small molecular subtype. This is a fundamentally different paradigm than KRAS G12C inhibition, and the clinical data suggest it works. What the Phase 1/2 Trial Actually Showed The trial, led by David Hong at MD Anderson and Brian Wolpin at Dana-Farber, was a dose escalation and expansion study with safety as the primary endpoint. Among 38 patients who received the 300 mg dose, the objective response rate was 29% and median overall survival was 15.6 months - roughly three times the historical benchmark for second-line therapy in this population. The primary endpoint was safety. While 96% of patients experienced adverse effects of any grade, only 30% had grade 3 or higher events. The most common toxicities were rash, diarrhea, stomatitis, mucositis, and fatigue. Half of patients required dose modifications, but no patients discontinued treatment due to adverse effects. For a disease where second-line cytotoxic regimens like nanoliposomal irinotecan/5-FU carry their own significant toxicity burden, a manageable profile at a therapeutically active dose is a meaningful clinical finding - not just a reassuring footnote. These data were compelling enough that the FDA granted orphan drug designation to daraxonrasib and cleared the path for the ongoing Phase 3 RASolute 302 trial, which is randomising patients to daraxonrasib versus investigator's choice of second-line chemotherapy. Clinical Scenario: A Patient Who Would Have Had No Good Options Paragraph 1: A 58-year-old man with stage IV pancreatic ductal adenocarcinoma progressed after six months on modified FOLFIRINOX. Molecular profiling confirmed KRAS G12D mutation. Performance status was ECOG 1. His oncologist had discussed gemcitabine/nab-paclitaxel as a second-line option but noted that expected median survival remained under eight months, and the patient was already experiencing peripheral neuropathy from prior oxaliplatin. Paragraph 2: Under the RASolute 302 trial eligibility criteria, this patient would be an ideal candidate: measurable disease, ECOG 0–1, RAS G12 mutation confirmed, prior systemic therapy complete. The 29% response rate seen in the Phase 1/2 cohort at 300 mg daily means nearly one in three patients like him would have had a measurable tumour response - with durable remissions reported among responders. His G12D mutation, previously untargetable, was directly addressed by daraxonrasib's multi-selective RAS(ON) mechanism. This is what broad-spectrum RAS inhibition looks like in practice. Situating This Within the Second-Line PDAC Treatment Decision Until RASolute 302 reports its primary endpoints, daraxonrasib is not yet standard of care. What clinicians need to understand is how this changes patient conversations right now. For patients with previously treated RAS-mutated PDAC who have maintained adequate performance status, clinical trial enrollment - specifically RASolute 302 - should be an active part of the discussion, not a last resort. The Phase 3 trial enrolled patients with ECOG 0–1, measurable disease per RECIST 1.1, and adequate organ function. The key practical distinction is mutation profiling. Daraxonrasib can target multiple RAS variants, not just G12C, which means molecular testing is no longer just a prognostic exercise in PDAC - it is a therapeutic prerequisite. Reflex somatic profiling at the time of diagnosis now has direct implications for second-line eligibility. If a patient progresses on first-line therapy without documented mutation status, the window for relevant second-line intervention may be narrowed unnecessarily. For community gastroenterologists and GI oncologists managing PDAC, the immediate action is to ensure molecular profiling is ordered at diagnosis, not after progression. The infrastructure for targeted therapy is being built now, and patients who arrive to second-line decisions without a molecular profile miss a rapidly closing opportunity. A Frequently Overlooked Point: RAS "Wild-Type" Patients Were Also Enrolled The RASolute 302 Phase 3 trial includes patients without an identified RAS mutation - so-called wild-type PDAC. This is worth noting because "RAS wild-type" at standard clinical sequencing does not guarantee truly RAS-independent biology; low-allele-fraction mutations and technical assay limitations are real confounders. More importantly, the trial's inclusion of wild-type patients means the signal from RASolute 302 will inform treatment decisions across the full PDAC population, not just the 90% with confirmed mutations. Clinicians should not automatically exclude a patient from referral to trial on the basis of wild-type status pending the trial's full reporting. Bottom Line for Clinical Practice Order reflex somatic molecular profiling at PDAC diagnosis , not at progression - RAS mutation subtype (G12D, G12V, G12R) now directly determines second-line trial eligibility. For patients progressing after first-line chemotherapy with ECOG 0–1 , discuss RASolute 302 enrollment alongside standard second-line options; the Phase 1/2 data show a 29% ORR and 15.6-month median OS at 300 mg daraxonrasib. Do not conflate KRAS G12C inhibitors (sotorasib, adagrasib) with daraxonrasib - the mechanism is fundamentally different; daraxonrasib targets RAS in its active GTP-bound state and covers the mutations that actually predominate in PDAC. Grade ≥3 toxicity was seen in 30% of patients - rash, diarrhea, and stomatitis are the signals to watch; no patients discontinued due to toxicity, but proactive monitoring and dose modification protocols matter. RASolute 302 is enrolling now - this is the moment to identify eligible patients early rather than at end-stage disease when performance status excludes trial participation. When you're managing a patient with progressive RAS-mutated PDAC and weighing second-line options, bring the clinical details to GastroAGI - it will walk through eligibility considerations, mutation-specific therapy options, and guideline-aligned management in real time. The landscape is shifting faster than any single update can capture.

GastroAGI TeamRead more

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

Gastroenterology Insights — Clinical Updates, Guides & Resources — Page 6

The Future of Gastroenterology Intelligence: How HIPAA-Ready, GI-Specialized AI Is Reshaping Care

HER2-Positive Gastroesophageal Cancer in 2026: How HERIZON-GEA-01 Resets the First-Line Standard

FIB-4 in MASLD: When to Trust It, When It Fails, and What to Do in the Grey Zone

Hepatic Encephalopathy in 2026: What the New ACG Guideline Changes About How You Diagnose, Treat, and Prevent It

ESGE Days 2026 Milan: What Every Gastroenterologist Needs to Take Back to Practice

Obesity is Plateauing in the West and Accelerating Everywhere Else: What That Means for Clinical Practice

Obesity Pharmacotherapy in 2026: How EASO's Complication-First Framework Changes the Way You Choose a Drug

H. pylori Treatment in 2026: Choosing the Right First-Line Regimen When Clarithromycin Is No Longer the Default

DDW 2026 Highlights: Day-by-Day Conference Insights for Gastroenterologists

Daraxonrasib in Previously Treated RAS-Mutated Pancreatic Cancer: What the NEJM Phase 1/2 Data Actually Means

For You

Core Tools

Explore

Gastroenterology Insights — Clinical Updates, Guides & Resources — Page 6

The Future of Gastroenterology Intelligence: How HIPAA-Ready, GI-Specialized AI Is Reshaping Care

HER2-Positive Gastroesophageal Cancer in 2026: How HERIZON-GEA-01 Resets the First-Line Standard

FIB-4 in MASLD: When to Trust It, When It Fails, and What to Do in the Grey Zone

Hepatic Encephalopathy in 2026: What the New ACG Guideline Changes About How You Diagnose, Treat, and Prevent It

ESGE Days 2026 Milan: What Every Gastroenterologist Needs to Take Back to Practice

Obesity is Plateauing in the West and Accelerating Everywhere Else: What That Means for Clinical Practice

Obesity Pharmacotherapy in 2026: How EASO's Complication-First Framework Changes the Way You Choose a Drug

H. pylori Treatment in 2026: Choosing the Right First-Line Regimen When Clarithromycin Is No Longer the Default

DDW 2026 Highlights: Day-by-Day Conference Insights for Gastroenterologists

Daraxonrasib in Previously Treated RAS-Mutated Pancreatic Cancer: What the NEJM Phase 1/2 Data Actually Means

For You

Core Tools

Explore